

UNITED STATES DEPARTMENT OF COMMERCE United States Pat nt and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.
09/180,798	11/16/98	DE VRIES	S	S-137-1103/S

\$\Psi 22847 HZ12/0921 SYNGENTA BIOTECHNOLOGY, INC. PATENT DEPARTMENT 3054 CORNWALLIS ROAD P.O. BOX 12257 RESEARCH TRIANGLE PARK NC 27709-2257

EXAMINER

MEHTA, A

ART UNIT PAPER NUMBER

1638

19

DATE MAILED: 09/21/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks

	Application No. Applicant(s)				
Advisory Action	09/180,798	DE VRIES ET AL.			
	Examiner	Art Unit			
	Ashwin D. Mehta	1638			
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence address			
THE REPLY FILED 04 September 2001 FAILS TO PLATHEREFORE, further action by the applicant is required to a final rejection under 37 CFR 1.113 may only be either: (1 condition for allowance; (2) a timely filed Notice of Appearance (1) appearance (1	void abandonment of this applic) a timely filed amendment whi	cation. A proper reply to a ch places the application in			
PERIOD FOR RE	PLY [check either a) or b)]				
 a)	isory Action, or (2) the date set forth in the an SIX MONTHS from the mailing date of	f the final rejection.			
Extensions of time may be obtained under 37 CFR 1.136(a). The dat have been filed is the date for purposes of determining the period of extens 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened (b) above, if checked. Any reply received by the Office later than three mo earned patent term adjustment. See 37 CFR 1.704(b).	sion and the corresponding amount of the statutory period for reply originally set in	fee. The appropriate extension fee under the final Office action; or (2) as set forth in			
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFI					
$2. \boxtimes$ The proposed amendment(s) will not be entered be	ecause:				
(a) I they raise new issues that would require further consideration and/or search (see NOTE below);					
(b) they raise the issue of new matter (see Note below);					
(c) they are not deemed to place the application i issues for appeal; and/or	n better form for appeal by mat	erially reducing or simplifying the			
(d) they present additional claims without cancel NOTE:	ing a corresponding number of	finally rejected claims.			
3. Applicant's reply has overcome the following reject	ion(s):				
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a s	eparate, timely filed amendment			
5.⊠ The a) affidavit, b) exhibit, or c) request for application in condition for allowance because: Se	r reconsideration has been cons <u>e Continuation Sheet</u> .	sidered but does NOT place the			
6. The affidavit or exhibit will NOT be considered bed raised by the Examiner in the final rejection.	cause it is not directed SOLELY	to issues which were newly			
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we					
The status of the claim(s) is (or will be) as follows:					
Claim(s) allowed:					
Claim(s) objected to:					
Claim(s) rejected: 47-82.					
Claim(s) withdrawn from consideration:					
8. \square The proposed drawing correction filed on is	a) approved or b) disapp	proved by the Examiner.			
9. Note the attached Information Disclosure Statemen	nt(s)(PTO-1449) Paper No(s)				
10. Other:					

Continuation of 5. does NOT place the application in condition for allowance because: it still encompasses DNA sequences that encode the amino acid sequence of SEQ ID NO: 21, which is not a full-legth protein. Further, Applicant's reply addresses only one of the outstanding rejections from the FINAL Office action.

AMY J. NELSON, PH.D PRIMARY EXAMINER

Amy Nel